CHYMEX
LOE Approachingbentiromide
NDAORALSOLUTION
Approved
Dec 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 11h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHYMEX (bentiromide) is an oral solution diagnostic agent approved in 1983 for pancreatic function assessment. It is not a therapeutic drug but a diagnostic test agent used to evaluate pancreatic exocrine sufficiency in patients with suspected pancreatic disease or malabsorption.
LOE Approaching
This legacy diagnostic agent faces declining utilization as modern imaging and biomarker-based diagnostics replace functional testing; commercial teams are likely consolidating.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHYMEX offers minimal career advancement opportunity given its legacy status, declining market relevance, and LOE-approaching lifecycle. Professionals assigned to this product should treat it as a short-term role and prioritize transition to higher-growth therapeutic assets within the portfolio.
Specialty Sales Representative (Diagnostics)Product Manager (Niche Diagnostics)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.